Department of Clinical and Experimental Medicine, University of Pisa, Via Savi 10, 56126 Pisa, Italy.
Department of Medico-Surgical Sciences and Biotechnologies, 'Sapienza' University of Rome, Corso della Repubblica 79, 04100 Latina, Italy.
Autoimmun Rev. 2017 Sep;16(9):946-950. doi: 10.1016/j.autrev.2017.07.006. Epub 2017 Jul 8.
Recently the importance of CXCL10 in the pathogenesis of non-segmental vitiligo (NSV) and autoimmune thyroid disorders (AITD) has been shown. No data are present about chemokines CXCL10 (Th1 prototype) and CCL2 (Th2 prototype) circulating levels in NSV patients with/without thyroiditis (AT). Serum CXCL10 and CCL2 have been measured in 50 consecutive NSV patients, in 40 consecutive patients with NSV and AT (NSV+AT), in 50 sex- and age-matched controls without AT (control 1) and in 40 sex- and age-matched patients with AT without NSV (control 2). Serum CXCL10 levels were significantly higher in control 2, than in control 1 (P=0.001; ANOVA). NSV patients have serum CXCL10 levels significantly higher than control 1, or control 2 (P=0.001). NSV+AT patients have serum CXCL10 levels higher than control 1, or 2 (P<0.001), and than NSV (P=0.01). In conclusion, we first demonstrate high serum CXCL10 in NSV patients, overall in presence of AT and hypothyroidism, suggesting the importance of a common Th1 immune response in their immune-pathogenesis. To evaluate if serum CXCL10 might be used as a clinical marker of NSV and/or AT further studies are needed.
最近已经表明,CXCL10 在非节段性白癜风(NSV)和自身免疫性甲状腺疾病(AITD)发病机制中的重要性。目前尚无关于 CXCL10(Th1 原型)和 CCL2(Th2 原型)循环水平在有/无甲状腺炎(AT)的 NSV 患者中的数据。在 50 例连续的 NSV 患者、40 例 NSV 合并 AT(NSV+AT)患者、50 例性别和年龄匹配的无 AT 对照组(对照组 1)和 40 例性别和年龄匹配的无 NSV AT 患者(对照组 2)中测量了血清 CXCL10 和 CCL2。对照组 2 的血清 CXCL10 水平明显高于对照组 1(P=0.001;ANOVA)。NSV 患者的血清 CXCL10 水平明显高于对照组 1 或对照组 2(P=0.001)。NSV+AT 患者的血清 CXCL10 水平高于对照组 1 或对照组 2(P<0.001),也高于 NSV(P=0.01)。总之,我们首次证明 NSV 患者的血清 CXCL10 水平升高,尤其是在合并 AT 和甲状腺功能减退时,这表明共同的 Th1 免疫反应在其免疫发病机制中很重要。为了评估血清 CXCL10 是否可以作为 NSV 和/或 AT 的临床标志物,还需要进一步研究。